Tags

Type your tag names separated by a space and hit enter

Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Pharmacoepidemiol Drug Saf. 2005 Jun; 14(6):407-15.PD

Abstract

PURPOSE

Previous research has suggested an association between use of atypical antipsychotics and onset of diabetes mellitus. We sought to compare the incidence of new onset diabetes among patients receiving atypical antipsychotics, traditional antipsychotics or antidepressants.

METHODS

Retrospective cohort study of outpatients with claims for atypical antipsychotics (n = 10 265) compared to controls with claims for traditional antipsychotics (n = 4607), antidepressants (n = 60 856) or antibiotics (n = 59 878) in the administrative claims database of a large pharmaceutical benefit manager between June 2000 and May 2002. Main outcome measures were adjusted and unadjusted incidence rates of diabetes (new cases per 1000 per year) in a 12-month period, as measured using new prescriptions for antidiabetic drugs after a 6-month lead-in period.

RESULTS

Annual unadjusted incidence rates of diabetes (new cases per 1000 per year) were 7.5 for atypical antipsychotics, 11.3 for traditional antipsychotics, 7.8 for antidepressants and 5.1 for antibiotics. In multivariable analyses, age, male sex and Chronic Disease Score were associated with greater odds of diabetes onset. There were no statistically significant differences in outcome between the atypical antipsychotic, traditional antipsychotic and antidepressant groups. Multivariable comparisons among specific agents showed increased odds of diabetes for clozapine, olanzapine, ziprasidone and thioridazine (relative to risperidone), but these comparisons did not reach statistical significance.

CONCLUSIONS

In a large prescription claims database, outpatients taking atypical antipsychotics did not have higher rates of diabetes onset, compared to subjects taking traditional antipsychotics or antidepressants.

Authors+Show Affiliations

Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA. truls.ostbye@duke.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15372671

Citation

Østbye, Truls, et al. "Atypical Antipsychotic Drugs and Diabetes Mellitus in a Large Outpatient Population: a Retrospective Cohort Study." Pharmacoepidemiology and Drug Safety, vol. 14, no. 6, 2005, pp. 407-15.
Østbye T, Curtis LH, Masselink LE, et al. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2005;14(6):407-15.
Østbye, T., Curtis, L. H., Masselink, L. E., Hutchison, S., Wright, A., Dans, P. E., Schulman, K. A., & Krishnan, R. R. (2005). Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiology and Drug Safety, 14(6), 407-15.
Østbye T, et al. Atypical Antipsychotic Drugs and Diabetes Mellitus in a Large Outpatient Population: a Retrospective Cohort Study. Pharmacoepidemiol Drug Saf. 2005;14(6):407-15. PubMed PMID: 15372671.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. AU - Østbye,Truls, AU - Curtis,Lesley H, AU - Masselink,Leah E, AU - Hutchison,Steve, AU - Wright,Alan, AU - Dans,Peter E, AU - Schulman,Kevin A, AU - Krishnan,Ranga R, PY - 2004/9/17/pubmed PY - 2006/4/20/medline PY - 2004/9/17/entrez SP - 407 EP - 15 JF - Pharmacoepidemiology and drug safety JO - Pharmacoepidemiol Drug Saf VL - 14 IS - 6 N2 - PURPOSE: Previous research has suggested an association between use of atypical antipsychotics and onset of diabetes mellitus. We sought to compare the incidence of new onset diabetes among patients receiving atypical antipsychotics, traditional antipsychotics or antidepressants. METHODS: Retrospective cohort study of outpatients with claims for atypical antipsychotics (n = 10 265) compared to controls with claims for traditional antipsychotics (n = 4607), antidepressants (n = 60 856) or antibiotics (n = 59 878) in the administrative claims database of a large pharmaceutical benefit manager between June 2000 and May 2002. Main outcome measures were adjusted and unadjusted incidence rates of diabetes (new cases per 1000 per year) in a 12-month period, as measured using new prescriptions for antidiabetic drugs after a 6-month lead-in period. RESULTS: Annual unadjusted incidence rates of diabetes (new cases per 1000 per year) were 7.5 for atypical antipsychotics, 11.3 for traditional antipsychotics, 7.8 for antidepressants and 5.1 for antibiotics. In multivariable analyses, age, male sex and Chronic Disease Score were associated with greater odds of diabetes onset. There were no statistically significant differences in outcome between the atypical antipsychotic, traditional antipsychotic and antidepressant groups. Multivariable comparisons among specific agents showed increased odds of diabetes for clozapine, olanzapine, ziprasidone and thioridazine (relative to risperidone), but these comparisons did not reach statistical significance. CONCLUSIONS: In a large prescription claims database, outpatients taking atypical antipsychotics did not have higher rates of diabetes onset, compared to subjects taking traditional antipsychotics or antidepressants. SN - 1053-8569 UR - https://www.unboundmedicine.com/medline/citation/15372671/Atypical_antipsychotic_drugs_and_diabetes_mellitus_in_a_large_outpatient_population:_a_retrospective_cohort_study_ L2 - https://doi.org/10.1002/pds.1016 DB - PRIME DP - Unbound Medicine ER -